Mirum Pharmaceuticals (MIRM) Liabilities and Shareholders Equity (2018 - 2026)
Mirum Pharmaceuticals (MIRM) posted quarterly Liabilities and Shareholders Equity of $890.9 million for Q1 2026, up 29.07% year-over-year from $690.2 million in Q1 2025, and up 5.71% quarter-over-quarter from $842.8 million in Q4 2025.
Mirum Pharmaceuticals (MIRM) Liabilities and Shareholders Equity (2018 - 2026) Analysis & Trends
Mirum Pharmaceuticals' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $890.9 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 29.07% year-over-year to $890.9 million; the TTM figure through Mar 2026 stood at $3.2 billion (up 20.64% YoY), while the FY2025 annual figure was $842.8 million, up 25.65% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $890.9 million, up from $842.8 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $890.9 million in Q1 2026, with the low at $278.1 million in Q1 2022.
- The 5-year median for Liabilities and Shareholders Equity is $652.0 million (2024), against an average of $585.5 million.
- Peak annual rise in Liabilities and Shareholders Equity reached 95.47% in 2024, while the deepest fall reached 2.65% in 2024.
- Mirum Pharmaceuticals' Liabilities and Shareholders Equity stood at $352.9 million in 2022, then surged by 83.23% to $646.6 million in 2023, then gained by 3.73% to $670.8 million in 2024, then grew by 25.65% to $842.8 million in 2025, then gained by 5.71% to $890.9 million in 2026.
- Business Quant data shows MIRM's Liabilities and Shareholders Equity at $890.9 million in Q1 2026, $842.8 million in Q4 2025, and $785.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Mirum Pharmaceuticals | 6.52 Bn | 6.08 Bn | 145.90 Mn | 1.04 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.04 Bn |
| Mar 31, 2026 | 890.92 Mn |
| Dec 31, 2025 | 842.81 Mn |
| Sep 30, 2025 | 785.12 Mn |
| Jun 30, 2025 | 725.83 Mn |
| Mar 31, 2025 | 690.25 Mn |
| Dec 31, 2024 | 670.75 Mn |
| Sep 30, 2024 | 667.89 Mn |
| Jun 30, 2024 | 660.75 Mn |
| Mar 31, 2024 | 651.96 Mn |
| Dec 31, 2023 | 646.62 Mn |
| Sep 30, 2023 | 650.64 Mn |
| Jun 30, 2023 | 443.59 Mn |
| Mar 31, 2023 | 333.53 Mn |
| Dec 31, 2022 | 352.91 Mn |
| Sep 30, 2022 | 364.35 Mn |
| Jun 30, 2022 | 297.23 Mn |
| Mar 31, 2022 | 278.15 Mn |
| Dec 31, 2021 | 294.65 Mn |
| Sep 30, 2021 | 235.17 Mn |